A detailed history of Gladius Capital Management LP transactions in Eli Lilly & CO stock. As of the latest transaction made, Gladius Capital Management LP holds 3,981 shares of LLY stock, worth $3.04 Million. This represents 2.12% of its overall portfolio holdings.

Number of Shares
3,981
Previous 3,981 -0.0%
Holding current value
$3.04 Million
Previous $3.53 Million -0.0%
% of portfolio
2.12%
Previous 2.12%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$772.14 - $960.02 $2.14 Million - $2.66 Million
2,774 Added 229.83%
3,981 $3.53 Million
Q2 2024

Jul 18, 2024

BUY
$724.87 - $909.04 $47,841 - $59,996
66 Added 5.78%
1,207 $1.09 Million
Q1 2024

May 14, 2024

SELL
$592.2 - $792.28 $37,308 - $49,913
-63 Reduced 5.23%
1,141 $887,000
Q4 2023

Feb 07, 2024

SELL
$525.19 - $619.13 $541,470 - $638,323
-1,031 Reduced 46.13%
1,204 $701,000
Q3 2023

Oct 10, 2023

BUY
$434.7 - $599.3 $971,554 - $1.34 Million
2,235 New
2,235 $1.2 Million
Q1 2023

Dec 18, 2023

SELL
$310.63 - $364.82 $693,326 - $814,278
-2,232 Reduced 99.87%
3 $1,000
Q1 2023

May 09, 2023

SELL
$310.63 - $364.82 $378,347 - $444,350
-1,218 Reduced 99.75%
3 $2,000
Q4 2022

Dec 18, 2023

SELL
$321.55 - $374.67 $326,051 - $379,915
-1,014 Reduced 45.37%
1,221 $446,000
Q4 2022

Feb 02, 2023

SELL
$321.55 - $374.67 $183,926 - $214,311
-572 Reduced 31.9%
1,221 $447,000
Q3 2022

Nov 14, 2022

BUY
$296.48 - $337.87 $498,975 - $568,635
1,683 Added 1530.0%
1,793 $580,000
Q2 2022

Aug 10, 2022

SELL
$278.73 - $327.27 $49,056 - $57,599
-176 Reduced 61.54%
110 $36,000
Q1 2022

Apr 29, 2022

BUY
$234.69 - $291.66 $55,621 - $69,123
237 Added 483.67%
286 $82,000
Q4 2021

Feb 08, 2022

BUY
$224.85 - $279.04 $11,017 - $13,672
49 New
49 $14,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $727B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Gladius Capital Management LP Portfolio

Follow Gladius Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Gladius Capital Management LP with notifications on news.